Potential opportunity size greater than PKD in B* unrisked modellingPYC’s renal program in Polycystic kidney disease (PKD) supports ~50% of PT today, but when looking at our unrisked valuation ($18/sh assuming 100% probability of success for all programs) PMS reflects a greater opportunity vs PKD (B*e $3.5b EV vs $3.1b EV respectively).
—//—
Barrenjoey’s Mellisa Benson is suggesting this new drug could actually prove to be bigger than PCKD
PYC seem to now have 2 blockbuster opportunities in their pipeline
Ann: Fourth Drug Program Progressing to Human Trials, page-4
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.36 |
Change
0.005(0.37%) |
Mkt cap ! $793.2M | |||
| Open | High | Low | Value | Volume |
| $1.40 | $1.40 | $1.36 | $211.9K | 152.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4103 | $1.36 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.39 | 2028 | 1 |
View Market Depth
| Last trade - 16.10pm 18/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |